The Christie Hospital
The Christie Hospital
Manchester, United Kingdom13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06635824 | |
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT04663347 | |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06731478 | |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2026-07-02 | NCT06819007 | |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, monoclonal gammopathy, myeloid leukemia, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-06-24 | NCT04068597 | |
| Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-06-22 | NCT05004064 | |
| Personalized Medicine for Advanced Biliary Cancer Patients | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract disorder, neoplasm | Recruiting | Phase 3 | 2026-05-19 | NCT05615818 | |
| Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-04-30 | NCT04546620 | |
| PreOperative Endocrine Therapy for Individualised Care With Abemaciclib | Breast Cancer Female | Active, not recruiting | Phase 3 | 2026-01-14 | NCT04584853 | |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Prostatic Neoplasms, Castration-Resistant, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, fibromatosis, gingival, 2, gastric cancer, gastric neoplasm, gonadal disorder, hepatocellular carcinoma, lethal congenital contracture syndrome 2, liver disorder, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, stomach disorder, triple-negative breast carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-08-11 | NCT05057013 | |
| A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-07-28 | NCT06045910 | |
| Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, skin disorder, skin neoplasm, uveal disorder, uveal melanoma | Active, not recruiting | Phase 2 | 2025-07-17 | NCT05315258 | |
| Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma | Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, neoplasm, plasma cell neoplasm, plasmacytoma | Active, not recruiting | Phase 3 | 2022-12-23 | NCT02544308 |